Table 4.
Cox Proportional Hazard Analysis on Primary colony-stimulating factor (CSF) use and overall survival among patients receiving chemotherapy
| Overall Survival among all patients |
|||||
|---|---|---|---|---|---|
| Characteristics | Univariable |
Multivariable |
|||
| N(%) | HR | 95% CI | HR | 95% CI | |
| Prophylactic CSF adminstrations | |||||
| 0–1 | 12,293 (93%) | 1.00 | 1.00 | ||
| 2 | 213 (1.6%) | 1.18 | 1.01 – 1.39 | 1.04 | 0.89 – 1.22 |
| 3–4 | 226 (1.7%) | 1.04 | 0.88 – 1.22 | 1.01 | 0.85 – 1.19 |
| 5–9 | 252 (1.9%) | 1.06 | 0.91 – 1.23 | 1.10 | 0.95 – 1.29 |
| 10+ | 219 (1.7%) | 0.93 | 0.78 – 1.10 | 1.03 | 0.87 – 1.22 |
| Year of Diagnosis | |||||
| 1992–1995 | 3,596 (27%) | 1.00 | 1.00 | ||
| 1996–1999 | 3,764 (29%) | 0.90 | 0.86 – 0.95 | 0.89 | 0.84 – 0.94 |
| 2000–2002 | 5,843 (44%) | 0.75 | 0.71 – 0.79 | 0.87 | 0.82 – 0.92 |
| Urban Residence | |||||
| Yes | 1,326 (10%) | 1.00 | - | ||
| No | 11,877 (90%) | 0.99 | 0.92 – 1.06 | - | |
| Age at diagnosis (continuous) | 74.94 (6.35) | 1.05 | 1.046 – 1.053 | 1.05 | 1.046 – 1.054 |
| Gender | |||||
| Female | 6,152 (47%) | 1.00 | |||
| Male | 7,051 (53%) | 0.79 | 0.76 – 0.82 | 0.79 | 0.77 – 0.83 |
| Race | |||||
| Non-Hispanic White | 11,776 | 1.00 | |||
| Hispanic | 236 | 0.89 | 0.76 – 1.05 | 0.81 | 0.69 – 0.96 |
| Black | 441 | 1.16 | 1.04 – 1.30 | 1.09 | 0.97 – 1.22 |
| Asian | 404 | 0.95 | 0.84 – 1.07 | 0.87 | 0.77 – 0.99 |
| Other | 304 | 1.36 | 1.19 – 1.54 | 1.24 | 1.09 – 1.42 |
| Marital Status | |||||
| Yes | 7,797 | 1.00 | |||
| No | 4,838 | 1.00 | 0.99 – 1.02 | - | |
| SES Quartile | |||||
| 1 (High) | 3,376 | 1.00 | 1.00 | ||
| 2 | 3,251 | 0.99 | 0.94 – 1.06 | 1.01 | 0.96 – 1.08 |
| 3 | 3,305 | 1.04 | 0.98 – 1.10 | 1.04 | 0.98 – 1.11 |
| 4 (Low) | 3,065 | 1.13 | 1.09 – 1.20 | 1.12 | 1.05 – 1.19 |
| Histology | |||||
| Diffuse Large B-cell | 5,861 | 1.00 | 1.00 | ||
| Follicular | 2,428 | 0.65 | 0.61 – 0.69 | 0.72 | 0.67 – 0.77 |
| Other | 3,665 | 0.93 | 0.88 – 0.98 | 0.90 | 0.86 – 0.96 |
| Stage at Diagnosis | |||||
| I | 3,564 | 1.00 | 1.00 | ||
| II | 2,214 | 1.19 | 1.11 – 1.27 | 1.23 | 1.15 – 1.31 |
| III | 1,971 | 1.46 | 1.36 – 1.56 | 1.60 | 1.49 – 1.71 |
| IV | 4,519 | 1.57 | 1.49 – 1.66 | 1.74 | 1.64 – 1.84 |
| Comorbidity Score | |||||
| 0 | 8,216 (62%) | 1.00 | |||
| 1 | 3,148 (24%) | 1.36 | 1.30 – 1.43 | 1.28 | 1.21 – 1.34 |
| ≥2 | 1,839 (14%) | 1.90 | 1.80 – 2.02 | 1.75 | 1.65 – 1.86 |
| Chemotherapy | |||||
| Duration (DOS) | 18.9 (23.1) | 0.994 | 0.992 – 0.995 | 0.992 | 0.990 – 0.993 |
| Chemotherapy Agent (yes vs. no) | |||||
| Alkylating Agents | 10,951 (83%) | 1.11 | 1.05 – 1.18 | 1.20 | 1.14 – 1.27 |
| Topo-isomerase II inhibitor | 3,328 (25%) | 1.37 | 1.31 – 1.43 | 0.96 | 0.92 – 1.02 |
| Anthracyclines | 7,068 (54%) | 0.85 | 0.81 – 0.88 | 1.36 | 1.29 – 1.44 |
| Antimetabolite | 3,148 (24%) | 1.15 | 1.10 – 1.20 | 1.25 | 1.13 – 1.39 |
| Platinums | 520 (4%) | 1.23 | 1.11 – 1.36 | 1.12 | 0.92 – 1.37 |
| Taxanes | 132 (1%) | 1.11 | 0.91 – 1.36 | 1.10 | 1.01 – 1.19 |
| Vinca Alkaloids | 10,718 (82%) | 1.08 | 1.02 – 1.14 | 1.20 | 1.10 – 1.31 |
| Non-anthracycline antibiotics | 711 (5%) | 1.41 | 1.30 – 1.54 | 0.70 | 0.67 – 0.73 |
| Targeted therapy | 6,937 (52%) | 0.62 | 0.60 – 0.65 | 1.13 | 1.07 – 1.20 |
| Other | 1,941 (15%) | 1.19 | 1.13 – 1.26 | 1.00 | 0.96 – 1.05 |
| Radiation Therapy | |||||
| No | 8,194 (62%) | 1.00 | |||
| Yes | 5,009 (38%) | 0.92 | 0.88 – 0.96 | 1.00 | 0.96 – 1.05 |